8-K: Anteris Technologies Achieves Clinical Milestone with 100 Patients Treated with DurAVR THV

Anteris Technologies announces a clinical milestone of treating over 100 patients worldwide with its DurAVR Transcatheter Heart Valve (THV).

Summary

• Anteris Technologies has reached a clinical milestone with over 100 patients treated with the DurAVR Transcatheter Heart Valve (THV).
• The DurAVR THV has been used in de novo aortic stenosis cases, valve-in-valve patients, and patients with complex anatomies like bicuspid aortic valves.
• 65 patients have completed the primary endpoint measures of safety and efficacy, showing hemodynamic benefit at 30 days post-implant.
• One-year efficacy data on 37 aortic stenosis patients demonstrates sustained large effective orifice areas (EOAs) and low mean pressure gradients (MPGs).
• The device has shown an excellent safety profile at one year, with no valve or cardiovascular-related mortality.
• The company remains on track to commence the DurAVR THV Pivotal Trial in the third quarter of 2025, pending FDA approval.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the achievement of a significant clinical milestone, strong clinical data, and forward progress towards a pivotal trial.

Positives

• The DurAVR THV has been successfully used in a variety of patients, including those with complex anatomies.
• The device has shown excellent hemodynamic performance and a strong safety profile.
• The company is progressing towards its registration trial.

Risks

• The commencement of the DurAVR THV Pivotal Trial is pending FDA approval, which introduces uncertainty.

Future Outlook

The company anticipates commencing the DurAVR THV Pivotal Trial in the third quarter of 2025, pending FDA approval.

Management Comments

• Chris Meduri, M.D., commented that the hemodynamic performance shows that DurAVR has the potential to restore natural heart valve function.
• Dr. Michael Reardon stated that they are building on a strong foundation of clinical evidence and remain committed to rigorous scientific evaluation.
• Wayne Paterson added that the results are clinically relevant and significantly differentiated to current therapies, confirming the value of the product for physicians and patients.

Industry Context

This announcement positions Anteris Technologies as a key player in the structural heart market, particularly in the treatment of aortic stenosis, with its innovative DurAVR THV.

Comparison to Industry Standards

• The DurAVR THV's biomimetic design and focus on replicating normal aortic blood flow differentiate it from traditional transcatheter heart valves.
• Competitors in the THV market include Edwards Lifesciences (Sapien valves) and Medtronic (Evolut valves).
• The reported sustained large EOAs and low MPGs at one year suggest potentially superior hemodynamic performance compared to some existing THVs, but direct head-to-head comparisons would be needed to confirm this.

Stakeholder Impact

• Shareholders will likely react positively to the clinical milestone and progress towards the pivotal trial.
• Physicians and patients may view the DurAVR THV as a promising new treatment option for aortic stenosis.

Next Steps

• Commence the DurAVR THV Pivotal Trial in the third quarter of 2025, pending FDA approval.

Key Dates

Keywords

DurAVR THV, Transcatheter Heart Valve, Aortic Stenosis, Clinical Milestone, Anteris Technologies, Heart Valve, Cardiovascular, Medical Device